Literature DB >> 9632169

Yield of mtDNA mutation analysis in 2,000 patients.

M H Liang1, L J Wong.   

Abstract

The multiplex polymerase chain reaction-allele specific oligonucleotides (PCR/ASO) dot blot hybridization method was used to detect 44 mitochondrial DNA point mutations in 2,000 patients suspected as having mitochondrial DNA disorders. These point mutations are classified into four categories. Category I consists of primary disease-causing, heteroplasmic point mutations. Homoplasmic nucleotide substitutions that have been reported to be possibly disease associated are in Category II. Homoplasmic nucleotide substitutions that are thought to be benign polymorphism are included in category III. The novel nucleotide substitutions recently discovered in our laboratory by single strand conformation polymorphism analysis are in category IV. Frequencies of these 44 nucleotide substitutions in 2,000 patients and 262 control individuals were studied. The results indicated that analysis of 12 recurrent disease-causing point mutations in category I identified 5.4% of the patients suspected as having mitochondrial DNA disorders. Since the mitochondrial disorders are a group of complex, heterogeneous, and multisystemic diseases, it is often difficult to confirm clinical diagnosis without molecular studies. Thus, the multiplex PCR/ASO method is an effective approach for initial screening of mtDNA mutations in patients suspected as having mitochondrial DNA disorders.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9632169

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  16 in total

Review 1.  The origin of cluster N2 of the energy-transducing NADH-quinone oxidoreductase: comparisons of phylogenetically related enzymes.

Authors:  T Yano; T Ohnishi
Journal:  J Bioenerg Biomembr       Date:  2001-06       Impact factor: 2.945

Review 2.  Human mitochondrial complex I in health and disease.

Authors:  J Smeitink; L van den Heuvel
Journal:  Am J Hum Genet       Date:  1999-06       Impact factor: 11.025

Review 3.  Mitochondrion and its related disorders: making a comeback.

Authors:  Xian-ning Zhang; Ming Qi
Journal:  J Zhejiang Univ Sci B       Date:  2008-02       Impact factor: 3.066

4.  Novel nucleotide substitutions in mitochondrial DNA.

Authors:  M H Liang; L J Wong
Journal:  J Inherit Metab Dis       Date:  1998-12       Impact factor: 4.982

5.  Bayesian network and mechanistic hierarchical structure modeling of increased likelihood of developing intractable childhood epilepsy from the combined effect of mtDNA variants, oxidative damage, and copy number.

Authors:  Brenda Luna; Sanjiv Bhatia; Changwon Yoo; Quentin Felty; David I Sandberg; Michael Duchowny; Ziad Khatib; Ian Miller; John Ragheb; Jayakar Prasanna; Deodutta Roy
Journal:  J Mol Neurosci       Date:  2014-07-16       Impact factor: 3.444

6.  Simultaneous detection and quantification of mitochondrial DNA deletion(s), depletion, and over-replication in patients with mitochondrial disease.

Authors:  Ren-Kui Bai; Lee-Jun C Wong
Journal:  J Mol Diagn       Date:  2005-11       Impact factor: 5.568

7.  Predominant cerebellar volume loss as a neuroradiologic feature of pediatric respiratory chain defects.

Authors:  Fernando Scaglia; Lee-Jun C Wong; Georgirene D Vladutiu; Jill V Hunter
Journal:  AJNR Am J Neuroradiol       Date:  2005-08       Impact factor: 3.825

8.  Illness-induced exacerbation of Leigh syndrome in a patient with the MTATP6 mutation, m. 9185 T>C.

Authors:  Russell P Saneto; Keshav K Singh
Journal:  Mitochondrion       Date:  2010-05-27       Impact factor: 4.160

9.  Detection of mitochondrial single nucleotide polymorphisms using a primer elongation reaction on oligonucleotide microarrays.

Authors:  F Erdogan; R Kirchner; W Mann; H H Ropers; U A Nuber
Journal:  Nucleic Acids Res       Date:  2001-04-01       Impact factor: 16.971

Review 10.  Mitochondrial disorders: prevalence, myths and advances.

Authors:  D R Thorburn
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.